The patient, R.C., finished her chemotherapy for breast cancer on June 4, 2007. At 58, she was ready for a better year, putting cancer treatment behind her and beginning her new life after cancer. In 2014, I was surprised to see R.C. on the schedule for chemotherapy education for FOLFOX (leucovorin calcium, fluorouracil, and oxaliplatin). Colorectal cancer had been discovered during a routine colonoscopy. When I met with her, she was obviously shaken and asked, "What happened? I thought I was done with cancer." .
BACKGROUND:Leptospirosis (LS) and hantavirus (HV) are rodent-borne diseases and share similar clinical manifestations, posing diagnostic challenges. METHODS:This retrospective study compared clinical characteristics, laboratory data, complications and outcomes of 33 LS and nine HV cases in Kaohsiung, Taiwan, from 2006 to 2021. RESULTS:Both LS and HV diseases had high rates of acute kidney injury (84.8% vs 66.7%) and hepatitis (65.6% vs 88.9%); LS showed more hyperbilirubinemia (70% vs 12.5% in HV, p=0.005), higher initial creatinine levels (2.9 vs 1.37, p=0.018) and elevated initial C-reactive protein (218.3 vs 28.6 mg/dl, p<0.001), but lower initial lymphocyte percentage (6.63% vs 14.2%, p=0.005) and platelets (138.7/mm3 vs 68.9, p=0.016) compared with HV. Microscopic hematuria was significantly more prevalent in LS (80% vs 28.65% in HV, p=0.016). Notably, the LS and HV groups exhibited statistically significant differences in thrombocytopenia (57.5% vs 100%, p=0.019), hyperbilirubinemia (70% vs 12.5%, p=0.005), shock (45.5% vs 0%, p=0.016) and hematuria (80% vs 28.6%, p=0.016). Neither group experienced fatalities. CONCLUSIONS:Fever, thrombocytopenia and acute kidney injury alert physicians to consider LS and HV for differential diagnosis. Elevated bilirubin, along with hematuria or shock, suggests a preferred diagnosis for LS.
Atrial fibrillation (AF) affects women and men differently, in particular when considering clinical presentation and quality of life. Despite having generally more symptoms, women are less likely to undergo AF ablation and have a higher rate of AF recurrence after undergoing ablation. Particularly, extra-PV ablation approaches have not proven advantageous versus pulmonary vein isolation (PVI) alone in women. The TAILORED-AF randomised clinical trial (NCT04702451) demonstrated a reduced rate of AF recurrence after a de novo catheter ablation targeting artificial intelligence (AI)-guided spatiotemporal dispersion in addition to PVI. To investigate whether an AI-guided, spatiotemporal based-ablation approach is superior to PVI in women with persistent AF. TAILORED-AF randomised patients to an AI-guided tailored ablation or PVI-only. We compared outcomes and dispersion characteristics between female and male patients. From the 370 patients treated in the TAILORED-AF trial, 77 (21%) were female. Women were significantly older (72±7 vs 65±12 years, p<0.001) and had a higher CHA2DS2-VASc score (3 [2-4] vs 2 [1-3], p<0.001). There was a larger percentage of women with a body mass index over 30kg/m2 (53% vs 40%, p=0.04), and a smaller percentage with diabetes or vascular disease (9 vs 19%, p=0.02 and 8% vs 17%, p=0.02, respectively). No difference was observed in AF duration (6±7 vs 6±5 months, p=0.31) and in left ventricular ejection fraction (55±10% vs 55±10%, p=0.81). Procedure and radiofrequency times and AF termination rates were not different between women and men (179±76 min vs 178±55, p=0.53, 45±21 min vs 41±16 min, p=0.29 and 64% vs 66%, p=0.84, respectively). There was no sex-related differences in complications following a Tailored ablation. Analyses of spatiotemporal dispersion location collected with electroanatomic mapping showed no sex-related differences in dispersion extent in the left atrium (LA) (13.7% in women vs 14.4% in men, p=0.88) or the right atrium (RA) (0.27% in women vs 0.82% in men, p=0.09). By contrast, the percentage of low voltage surface area in AF (<0.2mV) was significantly higher in women in the LA (30.7% [21.2-39.7] vs 18.0% [10.7-30.8], p<0.01). As expected based on previous reports, less women were free from AF or AF/atrial tachycardia (AT) after one procedure compared to men in the Tailored arm (74% vs 91% in men, log-rank p<0.001 and 56% vs 61% in men, log-rank p=0.04, respectively). Importantly, the rates of 12-month freedom from AF and AF/AT after a single procedure were significantly higher post-Tailored ablation compared to PVI only (74% vs 57%, log-rank p=0.01 and 56% vs 46%, log-rank p<0.01, respectively). Tailored ablation leads to a higher rate of freedom from any atrial arrhythmia after a single procedure in women.12-month follow-up outcomes
Background In a context of extending transcatheter aortic valve replacement (TAVR) to patients with a longer life expectancy, it is important to better document the incidence and outcomes of reintervention. Objectives The authors sought to evaluate the incidence, predictive factors, and long-term outcomes of surgical (explant TAVR) or transcatheter (redo TAVR) reintervention after TAVR. Methods Patients who had a TAVR between 2010 and 2022 recorded in the FRANCE 2 and FRANCE TAVI registries were included in the analysis. Cumulative incidence of early (≤1 year) and late (>1 year) reintervention was assessed using the Kalbfleisch and Prentice method to account for all-cause death as a competing risk. Patients who had reintervention for infective endocarditis were excluded. Long-term mortality was evaluated using Kaplan-Meier analysis. Results Among 72,850 patients included, the cumulative incidence of overall reintervention at 8 years was 1.7% including 591 patients who had redo TAVR and 111 patients who required explant TAVR with a low incidence of Bentall intervention. Reintervention occurred mostly early in 62.1% of cases and was more frequent in patients who had a mean aortic gradient >20 mm Hg immediately after index TAVR. Age and mean aortic gradient before TAVR and mean aortic gradient >20 mm Hg, aortic regurgitation ≥ grade 2, and percutaneous coronary intervention after TAVR were predictive of reintervention. Six-year mortality was high but was similar in patients who had early and late reintervention (76.2% vs 64.0%; P = 0.77). Conclusions Reintervention after TAVR remains rare and was mostly performed early after the procedure and by redo TAVR. Further studies are warranted, particularly in younger patients with longer life expectancy.